Peripheral Blood Cytokines Levels in Senegalese Women with Cervical Cancer during Chemotherapy
- 1 Immunology Unit, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
- 2 Immunology Unit, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
- 3 Immunology Unit, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
- 4 Joliot Curie Institute, Aristide Le Dantec Hospital, Dakar, Senegal
- 5 Joliot Curie Institute, Aristide Le Dantec Hospital, Dakar, Senegal
- 6 Immunology Unit, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
- 7 Unit of Human Genetics, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
- 8 Immunology Unit, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
- 9 Department of biology, FST, University Cheikh Anta Diop, Dakar, Senegal
- 10 Joliot Curie Institute, Aristide Le Dantec Hospital, Dakar, Senegal
- 11 Immunology Unit, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
- 12 Immunology Unit, FMPOS, University Cheikh Anta Diop, Dakar, Senegal
Abstract
Cervical cancer is the leading cause of cancer deaths of women in developing world. Several studies demonstrated evidences of inflammatory cytokines implication in cancer progression including in initiation, promotion and invasion by affecting the immune surveillance. Our aim was to measure blood circulating pro- and anti-inflammatory cytokines levels, their profiles according to treatment issue and relation with prognostic factors in cervical cancer during chemotherapy. Blood samples were collected from a cohort of 35 cervical cancer women and 42 women healthy controls (HC) with no history of malignancy. For each CP, three samples were taken at three-week intervals. The first one (S1) was taken before initiation of the chemotherapy protocol. S2 and S3 were samples collected respectively at day 21 and day 42. Cytokines levels were evaluated by ELISA. Mean age of patients was 54.1 year (35 - 77 yo). In groups, no relation was observed between age and cytokines levels. Before chemotherapy, high levels of IL-6, IL-4 and IFN- γ were observed in CP compared to HC ( p < 0 . 001) and at the same period, IL-10 and TNF- α levels were significantly low in CP ( p < 0 . 05) and negatively correlated ( r = — 0 . 79; p = 0 . 017). In this CP group, IL-4 levels were positively correlated between S1 and S2 ( r = 0 . 72; p = 0 . 002) and between S1 and S3 ( r = 0 . 74; p = 0 . 019). Similar correlations were observed for TNF- α levels: S1/S2 ( r = 0 . 54; p = 0 . 027), S2/S3 ( r = 0 . 82; p = 0 . 009) and S1/S3 ( r = 0 . 66; p = 0 . 036) with a significant increase of TNF- α in blood during treatment. Depending on chemotherapy’s efficacy, CP patients were separated into 1) non responders (NR), 2) partial responders (PR) and 3) good responders (GR). Compared to PR and GR groups, NR patients showed: a ) higher serum levels of IL-6, IL-10 and IFN- γ during the follow-up and b ) lower serum levels of IL-4 and TNF- α . In addition, serum levels of IL-4 were significantly higher in GR patients however TNF- α was the predominant cytokines in PR group. Our results highlight the variation of circulating cytokines such as IL-6, IL-10 and IFN- γ during cervical cancer chemotherapy. In addition, this study suggest ed that IL-4 and TNF- α might represent potential biomarkers candidate in cervical cancer. Applications in cancer management need further investigations particularly about the relevant prognostic indicator following chemotherapy and validation studies must provide more assurance for translation into clinical practice.
- Bray, F., Ferlay, J. and Soerjomataram, I. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
- Crosbie, E.J., Einstein, M.H. and Franceschi, S. (2013) Human Papillomavirus and Cervical Cancer. The Lancet, 382, 889-899. https://doi.org/10.1016/S0140-6736(13)60022-7
- ICO (2019) Information Centre on HPV and Cancer HPV Information Centre.
- NCCN (2020) Cervical Cancer.
- De Sanjose, S., Quint, W.G.V. and Alemany, L. (2010) Human Papillomavirus Genotype Attribution in Invasive Cervical Cancer: A Retrospective Cross-Sectional Worldwide Study. The Lancet Oncology, 11, 1048-1056. https://doi.org/10.1016/S1470-2045(10)70230-8
- Hu, X., Schwarz, J.K. and Lewis, J.S.A. (2010) microRNA Expression Signature for Cervical Cancer Prognosis. Cancer Research, 70, 1441-1448. https://doi.org/10.1158/0008-5472.CAN-09-3289
- Stevanović, S., Draper, L.M. and Langhan, M.M. (2015) Complete Regression of Metastatic Cervical Cancer after Treatment with Human Papillomavirus-Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology, 33, 1543. https://doi.org/10.1200/JCO.2014.58.9093
- Denny, L. (2012) Cervical Cancer: Prevention and Treatment. Discovery Medicine, 14, 125-131.
- Peters, W.A., Liu, P.Y. and Barrett, R.J.I. (2000) Concurrent Chemotherapy and Pelvic Radiation Therapy Compared with Pelvic Radiation Therapy Alone as Adjuvant Therapy after Radical Surgery in High-Risk Early-Stage Cancer of the Cervix. Journal of Clinical Oncology, 18, 1606-1613. https://doi.org/10.1200/JCO.2000.18.8.1606
- Whitney, C.W., Sause, W. and Bundy, B.N. (1999) Randomized Comparison of Fluorouracil plus Cisplatin versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix with Negative Paraaortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. Journal of Clinical Oncology, 17, 1339-1348. https://doi.org/10.1200/JCO.1999.17.5.1339
- Zhu, L., Zhang, X. and Sun, Z. (2020) SNRPB Promotes Cervical Cancer Progression through Repressing p53 Expression. Biomedicine & Pharmacotherapy, 125, Article ID: 109948. https://doi.org/10.1016/j.biopha.2020.109948
- Bidwell, J., Keen, L. and Gallagher, G. (2001) Cytokine Gene Polymorphism in Human Disease: On-Line Databases, Supplement 1. Genes & Immunity, 2, 61-70. https://doi.org/10.1038/sj.gene.6363733